Back to Search
Start Over
Evaluation of the MD Anderson tumor score for diffuse large B‐cell lymphoma in the rituximab era.
- Source :
- European Journal of Haematology; May2020, Vol. 104 Issue 5, p400-408, 9p
- Publication Year :
- 2020
-
Abstract
- Objectives: Diffuse large B‐cell lymphoma (DLBCL) is an aggressive heterogeneous lymphoma with standard treatment. However, 30%‐40% of patients still fail, so we should know which patients are candidates for alternative therapies. IPI is the main prognostic score but, in the rituximab era, it cannot identify a very high‐risk (HR) subset. The MD Anderson Cancer Center reported a score in the prerituximab era exclusively considering tumor‐related variables: Tumor Score (TS). We aim to validate TS in the rituximab era and to analyze its current potential role. Methods: From GELTAMO DLBCL registry, we selected those patients homogeneously treated with R‐CHOP (n = 1327). Results: Five‐years PFS and OS were 62% and 74%. All variables retained an independent prognostic role in the revised TS (R‐TS), identifying four different risk groups, with 5‐years PFS of 86%, 71%, 50%, and very HR (28%). With a further categorization of three variables of the original TS (Ann Arbor Stage, LDH and B2M), we generated a new index that allowed an improvement in HR assessment. Conclusions: (a) All variables of the original TS retain an independent prognostic role, and R‐TS remains predictive in the rituximab era; (b) R‐TS and additional categorization of LDH, B2M, and AA stage (enhanced TS) increased the ability to identify HR subsets. [ABSTRACT FROM AUTHOR]
- Subjects :
- LYMPHOMAS
INDEPENDENT variables
TUMORS
TALLIES
CHRONOLOGY
Subjects
Details
- Language :
- English
- ISSN :
- 09024441
- Volume :
- 104
- Issue :
- 5
- Database :
- Complementary Index
- Journal :
- European Journal of Haematology
- Publication Type :
- Academic Journal
- Accession number :
- 142767627
- Full Text :
- https://doi.org/10.1111/ejh.13364